Navigation Links
Glenmark's Novel Molecule for Diabetes, Melogliptin to Enter Phase III Trials
Date:6/24/2009

    Release Highlights

    - Melogliptin continues to demonstrate potential to be the
      best-in-class in achieving glycemic control with low incidence of
      hypoglycemia and neutral effect on body weight

    - Global Phase III trials likely to start by end 2009

    - IND approved by USFDA

    - Glenmark takes a step closer towards becoming the first
      Indian company to have a truly global innovative drug for the world

In the recently completed 12 week Phase IIb clinical trial in 494 patients with type 2 diabetes mellitus (T2DM), 'Melogliptin', Glenmark's investigational medicine from a new class of diabetes treatments called dipeptidyl peptidase 4 (DPP-4) inhibitors, improved glycemic control in patients with type 2 diabetes mellitus and exhibited excellent safety and tolerability profile. In addition, patients taking Melogliptin experienced low incidence of hypoglycemia and neutral effect on body weight.

In this 12-week, randomized, double-blind, placebo-controlled, parallel group study, Melogliptin significantly reduced HbA1c from baseline as compared to placebo with a mean average reduction of 0.75% in patients receiving 50mg twice daily dose (p<0001) and 0.60 % in patients receiving 100 mg once daily dose (p<.0001).

In a subgroup of patients with higher baseline HbA1c of 8.5%-10%, Melogliptin reduced HbA1c from baseline as compared to placebo with a mean average reduction of 0.88 % and 1.05 % in patients receiving 100mg once daily dose and 50mg twice daily dose respectively, which compares favorably to reported results of other DPP-4's.

The Phase IIb results for Melogliptin demonstrate potential for offering class leading improvements in glycemic control and metabolic function. Glenmark recently received IND approval from the USFDA to carry out a clinical study in the US. Glenmark continues to be in discussions with various licensing partners
'/>"/>

SOURCE Glenmark Pharmaceuticals Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Allied Minds Establishes New Company to Commercialize Novel UC Irvine Tinnitus Therapy
2. Calvert Research Licenses Novel Technology to Treat Age Related Macular Degeneration from Tulane University
3. Novavax and the NIH Agree to Evaluate a Virus-like Particle (VLP) Vaccine Candidate Against the Novel Influenza A (H1N1) Virus
4. Biomimetic-engineering design can replace spaghetti tangle of nanotubes in novel material
5. HHS Awards MedImmune Contract to Manufacture Live Attenuated Nasal Spray Vaccine for Novel Influenza A (H1N1)
6. Novel method predicts impact of a covert anthrax release
7. ImmunoVaccine Technologies Collaborates with NRC Institute for Biodiagnostics Atlantic to measure effectiveness of DepoVax(TM) with novel MRI Imaging
8. ImmunoVaccine Technologies Collaborates with NRC Institute for Biodiagnostics Atlantic to measure effectiveness of DepoVax(TM) with novel MRI Imagin
9. New nanotube coating enables novel laser power meter
10. Nano-sandwich triggers novel electron behavior
11. ChemoCentryx Identifies Novel Small Molecule C5aR Antagonist
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... In recent years, growing suspicion about ... product development and promotion has led to unprecedented levels ... by concerns about the insidious impact of commercialization of ... fines to the world’s biggest pharmas for illegal marketing ...
(Date:1/14/2014)... Jan. 14, 2014   Kinaxis ®, provider of RapidResponse ... sales and operations planning ( S&OP ) service, is proud ... , which will be held at the Hilton San Diego ... Kinaxis customer Elisabeth Kaszas , Director of Supply Chain ...
(Date:1/14/2014)... During the 1600’s through the 1800’s doctors contributed unknowingly ... this time period, doctors did not know that they needed ... death of vulnerable patients. In the same way, medical interns ... unwittingly transmitting herpes viruses to their patients. The CBCD explains. ...
(Date:1/14/2014)... January 14, 2014 Holloway America today ... of material test reports (MTRs) for all pressure vessels ... test results is particularly important for equipment that must ... MTR Library features search functionality that allows authorized users ...
Breaking Biology Technology:The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3Pressure Vessel Design and Fabrication Company Builds Database for Material Test Reports 2Pressure Vessel Design and Fabrication Company Builds Database for Material Test Reports 3
... Data Reported by Roche at 69th Scientific Sessions , ... Inc. (Nasdaq: VIAP ), a biotechnology company ... of cardiovascular and metabolic disease, announced today that preclinical ... inhibitors will be presented in a poster presentation at ...
... , Thursday, June 11th, 10:00 a.m. EDT , , ... ) announced today that the Company President and Chief Executive Officer, ... on Thursday, June 11th, 2009 at 10:00 a.m. EDT, to report ... a quarterly update of the Company. , , This call ...
... initial steps towards producing Influenza A (H1N1) VLP vaccine for ... 4 Novavax, Inc. (Nasdaq: NVAX ) and ... National Institute of Allergy and Infectious Diseases (NIAID), National Institutes ... the evaluation of a virus-like particle (VLP) vaccine candidate against ...
Cached Biology Technology:VIA Pharmaceuticals' DGAT1 Inhibitors Featured in American Diabetes Association Poster Presentation 2VIA Pharmaceuticals' DGAT1 Inhibitors Featured in American Diabetes Association Poster Presentation 3VIA Pharmaceuticals' DGAT1 Inhibitors Featured in American Diabetes Association Poster Presentation 4Repligen Announces Conference Call of Fourth Quarter and Fiscal Year 2009 Results 2Repligen Announces Conference Call of Fourth Quarter and Fiscal Year 2009 Results 3Novavax and the NIH Agree to Evaluate a Virus-like Particle (VLP) Vaccine Candidate Against the Novel Influenza A (H1N1) Virus 2Novavax and the NIH Agree to Evaluate a Virus-like Particle (VLP) Vaccine Candidate Against the Novel Influenza A (H1N1) Virus 3Novavax and the NIH Agree to Evaluate a Virus-like Particle (VLP) Vaccine Candidate Against the Novel Influenza A (H1N1) Virus 4
(Date:4/23/2014)... Wash. -- Like a hungry diner ripping open a ... into electricity must tear open a hydrogen molecule. Now ... holding onto the two halves of its hydrogen feast. ... how to make the catalyst work better for alternative ... scientists have shown precisely where the hydrogen halves end ...
(Date:4/23/2014)... Putnam Valley, NY. (Apr. 23 2014) ... human neural stem cells (hNSCs) into the brains ... differentiation after 22 and 24 months found that ... months and did not cause tumors. , The ... of Cell Transplantation but is currently ...
(Date:4/23/2014)... evidence of an interaction between prenatal smoking and ... children, especially in girls. , "The interesting issue ... smoking will have behavioral problems. Some might, ... Professor at Sam Houston State University, College of ... "One possible explanation for this is that ...
Breaking Biology News(10 mins):Halving hydrogen 2Halving hydrogen 3Halving hydrogen 4Study finds long-term survival of human neural stem cells transplanted into primate brain 2Genetics risk, prenatal smoking may predict behavioral problems 2
... we are strong and healthy and then we weaken and die ... about. But, in nature, the phenomenon of ageing shows an unexpected ... The University of Southern Denmark. Not all species weaken ... get stronger and less likely to die with age, while others ...
... The addition of a monoclonal antibody called gemtuzumab combined ... the risk of relapse and increase rates of disease-free ... Post-treatment relapse rates are a major indicator of potential ... The study (abstract #355) evaluated a total of 1,022 ...
... EPA grant, NJIT established its Technical Assistance to Brownfield ... allow NJIT to continue to provide communities with scientific, ... Specifically, the grant allows the NJIT TAB team to ... Mid-Atlantic region. NJIT TAB is comprised of planners, environmental ...
Cached Biology News:Surprising diversity in aging revealed in nature 2Surprising diversity in aging revealed in nature 3Targeted treatment can significantly reduce relapse in children with AML leukemia 2EPA awards $1 million grant to NJIT's Brownfield program 2
RAT ANTI MOUSE F4/80 ANTIGEN:BIOTIN Immunogen: Thioglycollate stimulated peritoneal macrophages from C57/BL mice...
RABBIT ANTI PARATHION...
Recombinant Rhesus Monkey IFN-Alpha...
2,4-Dinitrophenyl hapten is conjugated to BSA (Bovine Serum Albumin) protein through lysine....
Biology Products: